<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00023920</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02405</org_study_id>
    <secondary_id>ID00-323</secondary_id>
    <secondary_id>N01CM17003</secondary_id>
    <secondary_id>CDR0000068876</secondary_id>
    <nct_id>NCT00023920</nct_id>
  </id_info>
  <brief_title>Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia</brief_title>
  <official_title>A Phase II Study of Bevacizumab (rhuMab VEGF, NSC 704865), Idarubicin and Cytarabine in Patients With Chronic Myeloid Leukemia in Blast Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is to see if combining bevacizumab with idarubicin and cytarabine works&#xD;
      better in treating patients who have blast phase chronic myelogenous leukemia. Monoclonal&#xD;
      antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the&#xD;
      ability of cancer cells to grow and spread. Others find cancer cells and help kill them or&#xD;
      deliver cancer-killing substances to them. Drugs used in chemotherapy, such as idarubicin and&#xD;
      cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or&#xD;
      die. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment&#xD;
      for blast phase chronic myelogenous leukemia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the anti-leukemic activity of bevacizumab, idarubicin, and cytarabine in&#xD;
      patients with blastic phase chronic myelogenous leukemia.&#xD;
&#xD;
      II. Determine the toxicity profile of this regimen in these patients. III. Determine the&#xD;
      effect of bevacizumab on angiogenesis in these patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive bevacizumab IV over 90 minutes once on day -13. Patients then receive&#xD;
      bevacizumab IV over 90 minutes and idarubicin IV on days 1 and 15 and cytarabine&#xD;
      subcutaneously (SC) once daily beginning on day 1. Treatment repeats every 4 weeks for a&#xD;
      maximum of 3 courses. Patients with responding disease receive maintenance therapy comprising&#xD;
      bevacizumab IV over 90 minutes on days 1 and 15, idarubicin IV on day 1, and cytarabine SC&#xD;
      once daily beginning on day 1. Treatment repeats every 4 weeks for 2 years in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>July 2001</start_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in response rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Controlled toxicity rate graded according to NCI Common Toxicity Criteria</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <arm_group>
    <arm_group_label>Treatment (bevacizumab, idarubicin, cytarabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab IV over 90 minutes once on day -13. Patients then receive bevacizumab IV over 90 minutes and idarubicin IV on days 1 and 15 and cytarabine subcutaneously (SC) once daily beginning on day 1. Treatment repeats every 4 weeks for a maximum of 3 courses. Patients with responding disease receive maintenance therapy comprising bevacizumab IV over 90 minutes on days 1 and 15, idarubicin IV on day 1, and cytarabine SC once daily beginning on day 1. Treatment repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bevacizumab, idarubicin, cytarabine)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bevacizumab, idarubicin, cytarabine)</arm_group_label>
    <other_name>4-demethoxydaunorubicin</other_name>
    <other_name>4-DMDR</other_name>
    <other_name>DMDR</other_name>
    <other_name>IDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (bevacizumab, idarubicin, cytarabine)</arm_group_label>
    <other_name>ARA-C</other_name>
    <other_name>arabinofuranosylcytosine</other_name>
    <other_name>arabinosylcytosine</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Philadelphia chromosome-positive blastic phase chronic myelogenous&#xD;
             leukemia (CML), defined by 1 of the following:&#xD;
&#xD;
               -  At least 30% blasts in peripheral blood and/or bone marrow&#xD;
&#xD;
               -  Presence of extramedullary disease&#xD;
&#xD;
          -  Performance status - Zubrod 0-2&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
          -  No prior coagulopathies&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  INR less than 2&#xD;
&#xD;
          -  PTT no greater than 60 seconds&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No nephrotic syndrome&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No New York Heart Association class II-IV heart disease&#xD;
&#xD;
          -  No prior thrombotic events&#xD;
&#xD;
          -  LVEF â‰¥ 50%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens (no more than 1 regimen containing&#xD;
             cytarabine) for CML in blast crisis&#xD;
&#xD;
          -  Prior hydroxyurea allowed&#xD;
&#xD;
          -  Prior imatinib mesylate allowed&#xD;
&#xD;
          -  At least 10 days since prior anticoagulants&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Cortes</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

